Issue: November 2009
November 01, 2009
1 min read
Save

Exon-3 deleted GH receptor linked to long-term complications of acromegaly

Issue: November 2009
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Patients with long-term disease control of acromegaly and deletion of exon 3 of the growth hormone receptor (d3GHR) had an increased prevalence of irreversible comorbidities such as adenomatous colonic polyps, dolichocolon and osteoarthritis.

Researchers conducted a cross-sectional study to determine the impact of d3GHR on long-term disease control of acromegaly in 86 patients (mean age, 58 years). All patients had well-controlled disease for a mean of 14 years.

Six patients (7%) had two alleles encoding for the d3GHR isoform, 29 (34%) had one allele and 51 (59%) had two wild-type alleles.

Patients who were carriers of the d3GHR isoform had an increased prevalence of osteoarthritis (OR=5.2; 95% CI, 3.2-7.1), particularly of the hip, knee and distal interphalangeal joints of the hand. Carriers also had a higher prevalence of adenomatous polyps (OR=4.1; 95% CI, 2.4-5.6) and dolichocolon (OR=3.2; 95% CI, 1.8-4.6).

Researchers noted no significant difference in anthropometric parameters, bone mineral density, cardiovascular risk factors, nonvertebral fractures or type 2 diabetes between carriers and non-carriers of the d3GHR allele.

“Apparently, the ultimate impact of the d3GHR polymorphism on long-term complications of acromegaly is evident only on the irreversible effective of previous GH excess,” the researchers concluded.

Wassenaar MJE. J Clin Endocrinol Metab. 2009;doi:10.1210/jc.2009-1172.